GLTO vs. AYTU, SLGL, VBIV, INDP, COCP, GLYC, NERV, TLPH, KALA, and NRBO
Should you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Aytu BioPharma (AYTU), Sol-Gel Technologies (SLGL), VBI Vaccines (VBIV), Indaptus Therapeutics (INDP), Cocrystal Pharma (COCP), GlycoMimetics (GLYC), Minerva Neurosciences (NERV), Talphera (TLPH), KALA BIO (KALA), and NeuroBo Pharmaceuticals (NRBO). These companies are all part of the "pharmaceutical preparations" industry.
Aytu BioPharma (NASDAQ:AYTU) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Aytu BioPharma has higher revenue and earnings than Galecto. Aytu BioPharma is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.
Galecto has a net margin of 0.00% compared to Galecto's net margin of -14.60%. Galecto's return on equity of -31.31% beat Aytu BioPharma's return on equity.
In the previous week, Aytu BioPharma had 5 more articles in the media than Galecto. MarketBeat recorded 5 mentions for Aytu BioPharma and 0 mentions for Galecto. Galecto's average media sentiment score of 0.06 beat Aytu BioPharma's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the media.
Aytu BioPharma has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
Aytu BioPharma received 225 more outperform votes than Galecto when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 58.82% of users gave Galecto an outperform vote.
33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 4.3% of Aytu BioPharma shares are held by company insiders. Comparatively, 12.1% of Galecto shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Aytu BioPharma currently has a consensus target price of $5.00, suggesting a potential upside of 70.07%. Galecto has a consensus target price of $5.33, suggesting a potential upside of 758.69%. Given Aytu BioPharma's higher possible upside, analysts plainly believe Galecto is more favorable than Aytu BioPharma.
Summary
Aytu BioPharma beats Galecto on 10 of the 16 factors compared between the two stocks.
Get Galecto News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
